FDA Waves Bye to 11 Dormant Drug Files
Published Date: 2/20/2026
Notice
Summary
The FDA is officially pulling the plug on 11 drug approvals because the companies stopped selling these medicines. This change affects Masuu Global Solutions LLC and Breckenridge Pharmaceutical, with the withdrawal taking effect on March 23, 2026. No money penalties here—companies just asked to close these files, but they can apply again if they want.
Analyzed Economic Effects
3 provisions identified: 1 benefits, 1 costs, 1 mixed.
Existing Inventory May Still Be Dispensed
Drug products listed in the withdrawn ANDAs that are in inventory on March 23, 2026 may continue to be dispensed until those inventories are used up or the products reach their expiration dates. After that date, introducing those products into interstate commerce without an approved application would violate federal law.
FDA Withdraws 11 Generic Approvals
The FDA is withdrawing approval of 11 abbreviated new drug applications (ANDAs) as of March 23, 2026. Applicants informed the Agency that the products were no longer marketed and asked FDA to withdraw the approvals, including ANDAs filed by Masuu Global Solutions LLC and others listed in the notice.
Withdrawals Are Without Prejudice; Refiling Allowed
The notice says withdrawal of approval under 21 CFR 314.150(c) is without prejudice to refiling and that the applicants waived their opportunity for a hearing. Companies asked FDA to close these files and may reapply if they choose.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11740 — Medical Devices; Immunology and Microbiology Devices; Classification of the Spinal Muscular Atrophy Newborn Screening Test System
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
Previous / Next Documents
Previous: 2026-03410 — North Pacific Fishery Management Council; Public Meeting
The North Pacific Fishery Management Council’s Ecosystem Committee is meeting online on March 6, 2026, to talk about climate resilience, fish habitats, and groundfish management. This affects fishermen, environmental groups, and communities relying on Alaska’s fisheries. They’ll review plans tied to the Inflation Reduction Act and prepare for future policy updates—no big costs announced, but important decisions are on the horizon!
Next: 2026-03412 — Notice of Senior Executive Service Performance Review Board Appointments
The Department of the Interior just named a new team of leaders to review how top executives perform. These appointments start right away and help make sure the best people get recognized and rewarded. If you’re a senior executive, this means your work will be reviewed by this fresh group, but no changes to pay or timing were announced.